Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Innate Immunotherapeutics announces clinical trial fully enrolled and receives strong interest from potential Pharma partners
A Mutation in PMP2 Causes Dominant Demyelinating Charcot-Marie-Tooth Neuropathy.
Conversion of adult human peripheral blood mononuclear cells into induced neural stem cell by using episomal vectors.
Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases.
Corneal confocal microscopy in chronic inflammatory demyelinating polyneuropathy.
Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.
Inherited and acquired disorders of myelin: The underlying myelin pathology.
The epidemiology of alcohol consumption and multiple sclerosis: a review.
[Evolution of Devic's neuromyelitis optica spectrum disorders.]
The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue.
[Vaccines and central nervous system demyelinating diseases: New studies on the internet –not just new rumors].
Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis.
Exogenous leukemia inhibitory factor stimulates oligodendrocyte progenitor cell proliferation and enhances hippocampal remyelination.
Clinical Outcomes Following Surgical Management of Coexistent Cervical Stenosis and Multiple Sclerosis: A Cohort Controlled Analysis.
Errata-corrige. Extremely low-frequency pulsed magnetic fields and multiple sclerosis: effects on neurotransmission alone or also on immunomodulation? Building a working hypothesis.
Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease.
[New challenges in multiple sclerosis treatment].
MicroRNA-150: A potential regulator in pathogens infection and autoimmune diseases.
Substrate stiffness of endothelial cells directs LFA-1/ICAM-1 interaction: A physical trigger of immune-related diseases?
[NMO spectrum disorder].
B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation.
Editorial: Plasticity in Multiple Sclerosis: From Molecular to System Level, from Adaptation to Maladaptation.
Validation of the automated method VIENA: An accurate, precise, and robust measure of ventricular enlargement.
Melatonin reduces oxidative stress in the erythrocytes of multiple sclerosis patients with secondary progressive clinical course.
Stability of rating scale response category interpretations in neurological disorders.
Pages
« first
‹ previous
…
541
542
543
544
545
546
547
548
549
…
next ›
last »